Abstract:Abstract Background Viruses are obligate parasites that depend on host cells to provide the energy and molecular precursors necessary for successful infection. The main component of virus-induced metabolic reprogramming is the activation of glycolysis, which provides biomolecular resources for viral replication. However, little is known about the crosstalk between oncolytic viruses and host glycolytic processes. Methods A MTT assay was used to detect M1 virus-induced cell killing. Flow cytometry was used to monitor infection of M1 virus expressing the GFP reporter gene. qPCR and western blotting were used to detect gene expression. RNA sequencing was performed to evaluate gene expression under different drug treatments. Scanning electron microscopy was performed to visualize the endoplasmic reticulum (ER). Caspase activity was detected. Last, a mouse xenograft model was established to evaluate the antitumor effect in vivo. Most data were analyzed with a two-tailed Student’s t test or one-way ANOVA with Dunnett’s test for pairwise comparisons. Tumor volumes were analyzed by repeated measures of ANOVA. The Wilcoxon signed-rank test was used to compare nonnormally distributed data. Results Here, we showed that the glucose analog 2-deoxy- d -glucose (2-DG) inhibited infection by M1 virus, which we identified as a novel type of oncolytic virus, and decreased its oncolytic effect, indicating the dependence of M1 replication on glycolysis. In contrast, lonidamine, a reported hexokinase 2 (HK2) inhibitor, enhanced the infection and oncolytic effect of M1 virus independent of HK2. Further transcriptomic analysis revealed that downregulation of the antiviral immune response contributes to the lonidamine-mediated potentiation of the infection and oncolytic effect of M1 virus, and that MYC is the key factor in the pool of antiviral immune response factors inhibited by lonidamine. Moreover, lonidamine potentiated the irreversible ER stress-mediated apoptosis induced by M1 virus. Enhancement of M1′s oncolytic effect by lonidamine was also identified in vivo. Conclusions This research demonstrated the dependence of M1 virus on glycolysis and identified a candidate synergist for M1 virotherapy.

Alphavirus M1 Induces Apoptosis of Malignant Glioma Cells Via Downregulation and Nucleolar Translocation

Visualization of the Oncolytic Alphavirus M1 Life Cycle in Cancer Cells

Suppression of CCDC6 sensitizes tumor to oncolytic virus M1

Caspase- and p38-MAPK-dependent induction of apoptosis in A549 lung cancer cells by Newcastle disease virus

Inhibition of the mevalonate pathway enhances cancer cell oncolysis mediated by M1 virus

Effect of allicin on THP-1, MT-2 and wish cell apoptosis induced by vesicular stomatitis virus (VSV) and the molecular mechanism involved

Oncolytic Vaccinia Virus Inhibits Human Hepatocellular Carcinoma Mhcc97-H Cell Proliferation Via Endoplasmic Reticulum Stress, Autophagy and Wnt Pathways

Gli1 is a Potential Target for Alleviating Multidrug Resistance of Gliomas

Rabies virus matrix protein induces apoptosis by targeting mitochondria

Influence of Apoptin on Up-Regulation of the Expression of Bad and Bax

Marek's Disease Virus (<i>Gallid alphaherpesvirus</i> 2)-Encoded miR-M2-5p Simultaneously Promotes Cell Proliferation and Suppresses Apoptosis Through RBM24 and MYOD1-Mediated Signaling Pathways

Marek’s Disease Virus (Gallid alphaherpesvirus 2)-Encoded miR-M2-5p Simultaneously Promotes Cell Proliferation and Suppresses Apoptosis Through RBM24 and MYOD1-Mediated Signaling Pathways

Mink Enteritis Virus Infection Induces Mitochondrion-mediated Apoptosis by the Viral Nonstructural Protein 1.

Bovine herpesviruses induce different cell death forms in neuronal and glial-derived tumor cell cultures

Intravenous injections of the oncolytic virus M1 as a novel therapy for muscle-invasive bladder cancer

Avian leukosis virus subgroup J promotes cell proliferation and cell cycle progression through miR-221 by targeting CDKN1B

The Role of High Mobility Group AT-hook 1 in Viral Infections: Implications for Cancer Pathogenesis

Lonidamine potentiates the oncolytic efficiency of M1 virus independent of hexokinase 2 but via inhibition of antiviral immunity

Enhancing antitumor efficacy of oncolytic virus M1 via albendazole-sustained CD8+ T cell activation

MAPK pathway orchestrates gallid alphaherpesvirus 1 infection through the biphasic activation of MEK/ERK and p38 MAPK signaling

The aldehyde dehydrogenase ALDH1B1 exerts antiviral effects through the aggregation of the adaptor MAVS